{"id":78668,"date":"2025-11-12T13:04:09","date_gmt":"2025-11-12T13:04:09","guid":{"rendered":"https:\/\/www.europesays.com\/se\/78668\/"},"modified":"2025-11-12T13:04:09","modified_gmt":"2025-11-12T13:04:09","slug":"jag-trodde-nagot-var-fel-men-det-var-en-ny-cell","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/se\/78668\/","title":{"rendered":"\u201dJag trodde n\u00e5got var fel \u2013 men det var en ny cell\u201d"},"content":{"rendered":"<p>Bild:<\/p>\n<p> <img decoding=\"async\" src=\"https:\/\/www.europesays.com\/se\/wp-content\/uploads\/2025\/11\/rolf-kiessling_foto-linnea-bengtsson_custom20251106095341.webp.webp\" alt=\"Portr\u00e4tt av Rolf Kiessling.\"\/><\/p>\n<p>Rubrik:<\/p>\n<p> Rolf Kiessling.<br \/>\nFoto: Linnea Bengtsson<\/p>\n<p>Ber\u00e4ttat f\u00f6r: Ola Danielsson, f\u00f6rst publicerad i Medicinsk Vetenskap nr 3\/2025<\/p>\n<p>Som doktorand skulle <a href=\"https:\/\/ki.se\/personer\/rolf-kiessling\" data-entity-type=\"external\" rel=\"nofollow noopener\" target=\"_blank\">Rolf Kiessling<\/a> unders\u00f6ka hur T-celler, ett slags vit blodkropp, i m\u00f6ss reagerade p\u00e5 blodcancer. M\u00f6ssen fick f\u00f6rst ett vaccin som skulle l\u00e4ra immunf\u00f6rsvaret att attackera cancercellerna. Men n\u00e4r han sedan testade vita blodkroppar fr\u00e5n m\u00f6ss som inte vaccinerats, allts\u00e5 kontrollgruppen, s\u00e5g han att tum\u00f6rcellerna dog \u00e4nd\u00e5.<\/p>\n<p>&#8211; \u00a0Vi trodde f\u00f6rst att n\u00e5got var fel, men till slut ins\u00e5g vi att vi hade uppt\u00e4ckt n\u00e5got nytt: En vit blodkropp som kan d\u00f6da tum\u00f6rceller utan att f\u00f6rst l\u00e4ra sig det. Vi kallade den Natural Killer-cell \u2013 NK-cell \u2013 eftersom den verkade vara f\u00f6dd med den f\u00f6rm\u00e5gan, s\u00e4ger Rolf Kiessling, senior professor i experimentell onkologi vid institutionen f\u00f6r onkologi-patologi, Karolinska Institutet och \u00f6verl\u00e4kare, Tema Cancer, Karolinska Universitetssjukhuset.<\/p>\n<p>NK-celler \u00e4r en del av m\u00e4nniskans medf\u00f6dda immunf\u00f6rsvar. De patrullerar i blodet och sl\u00e5r snabbt till mot celler som b\u00e4r tecken p\u00e5 sjukdom \u2013 s\u00e4rskilt om de f\u00f6rs\u00f6ker undg\u00e5 T-cellernas \u00f6vervakning. Det finns ett stort intresse f\u00f6r att anv\u00e4nda NK-celler och T-celler som immunterapi mot cancer. L\u00e4ngst har man kommit med de mer potenta T-cellerna, ber\u00e4ttar Rolf Kiessling.<\/p>\n<p>&#8211; Men NK-cellerna har f\u00f6r\u00addelen att de inte beh\u00f6ver individanpassas p\u00e5 samma s\u00e4tt, vilket g\u00f6r att man fr\u00e5n samma givare kan framst\u00e4lla NK-celler f\u00f6r behandling av olika patienter.<\/p>\n<p>Nu leder han ett labb d\u00e4r vi utvecklar avancerade cellterapier \u2013 l\u00e4kemedel baserade p\u00e5 patientens egna immunceller.<\/p>\n<p>&#8211; Med en kombination av T-celler och tum\u00f6rvaccin har vi r\u00e4ddat livet p\u00e5 flera sv\u00e5rt sjuka patienter med metastaser i hela kroppen. Det k\u00e4nns bra att ha uppt\u00e4ckt NK-cellerna. Men den kliniska forskningen, att direkt hj\u00e4lpa patienter, \u00e4r det som ger mig den st\u00f6rsta tillfredsst\u00e4llelsen, s\u00e4ger Rolf Kiessling.<\/p>\n","protected":false},"excerpt":{"rendered":"Bild: Rubrik: Rolf Kiessling. Foto: Linnea Bengtsson Ber\u00e4ttat f\u00f6r: Ola Danielsson, f\u00f6rst publicerad i Medicinsk Vetenskap nr 3\/2025&hellip;\n","protected":false},"author":2,"featured_media":78669,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[69],"tags":[113,112,34,31,33,32,30],"class_list":{"0":"post-78668","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-halsa","8":"tag-halsa","9":"tag-health","10":"tag-se","11":"tag-svenska","12":"tag-sverige","13":"tag-sweden","14":"tag-swedish"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@se\/115536872422084248","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/posts\/78668","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/comments?post=78668"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/posts\/78668\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/media\/78669"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/media?parent=78668"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/categories?post=78668"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/tags?post=78668"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}